Stephanie N Chun, MD
Obstetrics/Gynecology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Office
- 1
- Since medical school
- 37 years
- Northwestern University Feinberg Medical School, 1989
Offices
1 location · Sfwomen'S Gyn Inc. · 2 clinicians in this group
Looking this up.
Hospitals listed: California Pacific Medical Center- Van Ness Campus. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chun’s office at (415) 563-9000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$7,472
Medicare paid this office $7,472 for 56 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 24 | $3,082 | $106 |
| Short return visit (20+ min) | 17 | $2,056 | $76 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 15 | $711 | $47 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 11 | $624 | $57 |
Who their Medicare patients are
56 Original Medicare patients in 2024. Average age 71 · Women 100% · Health risk score 0.56. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 46% · Diabetes 25%.
The office billed $18,665, Medicare allowed $9,881 and paid $7,472; for 95 services of 10 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 56 | 95 | 71 | 0.56 | $18,665 | $7,472 |
| 2023 | 59 | 110 | 69 | 0.64 | $20,343 | $7,355 |
| 2022 | 48 | 104 | 70 | 0.65 | $18,546 | $7,317 |
| 2021 | 50 | 90 | 70 | 0.66 | $14,080 | $6,121 |
| 2020 | 33 | 62 | 69 | 0.75 | $9,272 | $3,479 |
| 2019 | 43 | 72 | 69 | 1.17 | $11,175 | $4,489 |
| 2018 | 26 | 44 | 68 | 0.71 | $6,080 | $2,493 |
| 2017 | 34 | 56 | 69 | 0.70 | $11,740 | $4,390 |
| 2016 | 29 | 54 | 67 | 1.04 | $7,035 | $3,180 |
| 2015 | 28 | 46 | 69 | 0.72 | $7,540 | $3,172 |
| 2014 | 27 | 51 | 69 | 0.67 | $8,615 | $3,654 |
| 2013 | 27 | 51 | 73 | 0.74 | $7,990 | $3,425 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 41 | $1,922 | $47 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 25 | $1,367 | $55 |
| Return visit (30+ min) | 11 | $1,185 | $108 |
| Short return visit (20+ min) | 11 | $912 | $76 |
2022: 4 services
| Return visit (30+ min) | 25 | $3,109 | $111 |
| Short return visit (20+ min) | 16 | $1,234 | $65 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 23 | $1,066 | $46 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 16 | $851 | $53 |
2021: 4 services
| Return visit (30+ min) | 17 | $2,004 | $118 |
| Short return visit (20+ min) | 17 | $1,286 | $68 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 24 | $1,130 | $47 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 18 | $971 | $54 |
2020: 3 services
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 19 | $1,018 | $54 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 19 | $901 | $47 |
| Return visit (30+ min) | 13 | $896 | $69 |
2019: 3 services
| Return visit (30+ min) | 13 | $1,318 | $101 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 19 | $1,007 | $53 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 20 | $918 | $46 |
2018: 2 services
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 14 | $761 | $54 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 16 | $719 | $45 |
2017: 3 services
| Return visit (30+ min) | 13 | $1,390 | $99 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 13 | $724 | $56 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 14 | $644 | $46 |
2016: 1 service
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 15 | $691 | $46 |
2015: 1 service
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 11 | $507 | $46 |
2014: 2 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 21 | $955 | $45 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 16 | $888 | $55 |
2013: 3 services
| Return visit (30+ min) | 12 | $1,155 | $89 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 13 | $747 | $57 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 13 | $600 | $46 |
Drugs they prescribed that Part D paid
$35,760
Pharmacies billed $35,760 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 161) in 2024. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0%.
125 generic and 36 brand-name prescriptions · $35,760 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Estradiol | 20 | $1,834 | $92 |
| Progesterone | 24 | $931 | $39 |
Year by year
| 2024 | 161 | 59 | 0% (0) | 22% | $35,760 |
| 2023 | 136 | 45 | 0% (0) | 24% | $43,263 |
| 2022 | 135 | 47 | 0% (0) | 19% | $38,449 |
| 2021 | 100 | 41 | 0% (0) | 32% | $25,683 |
| 2020 | 66 | 33 | 0% (0) | None | $12,006 |
| 2019 | 69 | 23 | 0% (0) | 28% | $15,188 |
| 2018 | 59 | 21 | 0% (0) | 39% | $10,525 |
| 2017 | 99 | 29 | None | 15% | $15,789 |
| 2016 | 75 | 21 | None | 39% | $19,106 |
| 2015 | 80 | 19 | None | 48% | $16,425 |
| 2014 | 77 | 21 | None | 45% | $10,286 |
| 2013 | 84 | 20 | 0% (0) | 46% | $6,893 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Prolia | 15 | $25,435 | $1,696 |
| Estradiol | 24 | $2,877 | $120 |
| Progesterone | 11 | $883 | $80 |
| Valacyclovir | 13 | $282 | $22 |
2022: 3 drugs
| Prolia | 15 | $23,373 | $1,558 |
| Estradiol | 21 | $2,339 | $111 |
| Progesterone | 15 | $619 | $41 |
2021: 3 drugs
| Bijuva | 11 | $2,985 | $271 |
| Estradiol | 12 | $2,686 | $224 |
| Alendronate | 12 | $136 | $11 |
2020: 1 drug
| Estradiol | 11 | $3,437 | $312 |
2018: 1 drug
| Estradiol | 12 | $969 | $81 |
2017: 2 drugs
| Estradiol | 19 | $1,478 | $78 |
| Lidocaine | 11 | $1,322 | $120 |
2016: 2 drugs
| Lidocaine | 12 | $6,470 | $539 |
| Vagifem | 18 | $6,042 | $336 |
2015: 2 drugs
| Lidocaine | 16 | $5,274 | $330 |
| Vagifem | 17 | $3,556 | $209 |
2014: 1 drug
| Vagifem | 16 | $2,069 | $129 |
2013: 2 drugs
| Vagifem | 20 | $1,724 | $86 |
| Fluconazole | 11 | $37 | $3 |
Money from drug and device companies
$253 in 2025
| 2025 | 5 | 15 | None | $253 |
| 2024 | 6 | 13 | None | $288 |
| 2023 | 11 | 16 | None | $360 |
| 2022 | 10 | 30 | None | $652 |
| 2021 | 11 | 44 | None | $848 |
| 2020 | 8 | 46 | None | $942 |
| 2019 | 10 | 16 | None | $533 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Mayne Pharma Commercial | None | $114 | 9 payments
|
| Astellas Pharma US | Veozah | $81 | 3 payments
|
| Sumitomo Pharma America | Myfembree | $24 | 1 payment
|
| Millicent US | Femring | $18 | 1 payment
|
| Biogen | Zurzuvae | $17 | 1 payment
|
See all 15 published payments
| Mayne Pharma Commercial | Meals · 2025-12-10 | None | $12 |
| Sumitomo Pharma America | Meals · 2025-12-08 | Myfembree | $24 |
| Mayne Pharma Commercial | Meals · 2025-11-10 | None | $10 |
| Mayne Pharma Commercial | Meals · 2025-10-20 | None | $12 |
| Mayne Pharma Commercial | Meals · 2025-09-12 | None | $13 |
| Mayne Pharma Commercial | Meals · 2025-08-18 | None | $13 |
| Mayne Pharma Commercial | Meals · 2025-07-11 | None | $9 |
| Mayne Pharma Commercial | Meals · 2025-06-24 | None | $22 |
| Mayne Pharma Commercial | Meals · 2025-04-24 | None | $17 |
| Millicent US | Meals · 2025-03-31 | Femring | $18 |
| Mayne Pharma Commercial | Meals · 2025-03-28 | None | $7 |
| Astellas Pharma US | Meals · 2025-03-24 | Veozah | $32 |
| Biogen | Meals · 2025-03-07 | Zurzuvae | $17 |
| Astellas Pharma US | Meals · 2025-02-26 | Veozah | $23 |
| Astellas Pharma US | Meals · 2025-02-03 | Veozah | $26 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $288
| Astellas Pharma US | Veozah | $99 | 2 payments
|
| Millicent US | Femring | $59 | 3 payments
|
| Biogen | None | $50 | 2 payments
|
| Organon | Nexplanon | $36 | 2 payments
|
| Mayne Pharma Commercial | None | $25 | 3 payments
|
| Minerva Surgical | None | $19 | 1 payment
|
2023: $360
| Amgen | Evenity | $106 | 4 payments
|
| Sumitomo Pharma America | Myfembree | $46 | 2 payments
|
| Mayne Pharma Commercial | None | $35 | 2 payments
|
| Shield Therapeutics | Accrufer | $34 | 1 payment
|
| Medicem | Dilapan-S | $29 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Kyleena | $25 | 1 payment
|
| Ascend Therapeutics US | Estrogel | $25 | 1 payment
|
| Astellas Pharma US | Veozah | $21 | 1 payment
|
| AbbVie | Orilissa | $16 | 1 payment
|
| CooperSurgical | Paragard T 380a | $16 | 1 payment
|
| Organon | Nexplanon | $7 | 1 payment
|
2022: $652
| Abbvie | Oriahnn | $221 | 10 payments
|
| Amgen | Evenity | $132 | 7 payments
|
| Bayer HealthCare Pharmaceuticals | Kyleena | $58 | 2 payments
|
| Myovant Sciences | Myfembree | $54 | 2 payments
|
| Mayne Pharma | None | $51 | 2 payments
|
| TherapeuticsMD | Annovera | $43 | 2 payments
|
| Agile Therapeutics | Twirla | $36 | 2 payments
|
| Hologic | Acessa Provu System | $23 | 1 payment
|
| Avion Pharmaceuticals | Balcoltra | $17 | 1 payment
|
| Organon | Nexplanon | $17 | 1 payment
|
2021: $848
| AbbVie | Lo Loestrin Fe | $161 | 7 payments
|
| Myovant Sciences | Myfembree | $154 | 6 payments
|
| Amgen | Evenity | $137 | 6 payments
|
| Avion Pharmaceuticals | Balcoltra | $132 | 12 payments
|
| TherapeuticsMD | Annovera | $67 | 3 payments
|
| Mylan Pharmaceuticals | Xulane | $54 | 3 payments
|
| Organon | Nexplanon | $43 | 3 payments
|
| Roche Diagnostics | Cintec Plus Cytology | $29 | 1 payment
|
| Agile Therapeutics | Twirla | $26 | 1 payment
|
| CooperSurgical | Paragard | $23 | 1 payment
|
| Merck Sharp & Dohme | Nexplanon | $21 | 1 payment
|
2020: $942
| AbbVie | Orilissa | $288 | 9 payments
|
| TherapeuticsMD | Annovera | $223 | 13 payments
|
| Avion Pharmaceuticals | Balcoltra | $135 | 10 payments
|
| Bayer HealthCare Pharmaceuticals | Kyleena | $115 | 6 payments
|
| Amgen | Evenity | $100 | 4 payments
|
| Mylan Pharmaceuticals | Xulane | $43 | 2 payments
|
| AMAG Pharmaceuticals | Vyleesi | $23 | 1 payment
|
| CooperSurgical | Paragard | $16 | 1 payment
|
2019: $533
| Merck Sharp & Dohme | Gardasil | $145 | 3 payments
|
| Ethicon US | Surgicel Powder | $87 | 1 payment
|
| Amgen | Evenity | $87 | 3 payments
|
| TherapeuticsMD | Imvexxy | $69 | 2 payments
|
| AbbVie | Orilissa | $41 | 2 payments
|
| Vertical Pharmaceuticals | Osmolex Er | $27 | 1 payment
|
| AMAG Pharmaceuticals | Vyleesi | $25 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Kyleena | $20 | 1 payment
|
| CooperSurgical | Endosee | $17 | 1 payment
|
| Avion Pharmaceuticals | Prenate Mini | $15 | 1 payment
|
Professional record
- NPI
- 1285750943
- Licence
- CA G085621
- Trained
- Northwestern University Feinberg Medical School, 1989 · 37 years ago
- Group
- Sfwomen'S Gyn Inc.
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 3838 California St Rm 412, San Francisco, CA, 94118
- NPI first listed
- 2007-03-22
- NPI last updated
- 2025-07-10
- NPI record certified
- 2025-06-10
This is when the NPI record was last certified, not a medical board exam.